By Daniella Parra
Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) said its SQore platform, which transforms intravenous biologic medicines, particularly monoclonal antibodies (mAbs), into subcutaneous formulations.
The company said it reduced the viscosity of over 40 mAbs by up to 85%, addressing a common challenge in subcutaneous delivery. Additionally, there was a study where a caffeine-based excipient effectively reduced viscosity without affecting antibody properties, it said.
“The data reinforces the strength of our SQore platform in reformulating high-viscosity monoclonal antibody solutions and underscores the potential of caffeine and other core excipients as viscosity-reducing agents for subcutaneous monoclonal antibody formulations,” Robert Mahoney, Ph.D., Chief Scientific Officer at Comera, said. “Ultimately, the mission driving our research is to enhance convenience, decrease costs and increase compliance by reformulating therapies for patient-delivered SQ injections.”